Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first‐line therapy: A Korean multicenter study. Issue 7 (15th July 2014)

• Record Type: Journal Article
• Authors: Lee, Sangheun; Kim, Beom Kyung; Kim, Seung Up; Park, Soo Young; Kim, Ja Kyung; Lee, Hyun Woong; Park, Jun Yong; Kim, Do Young; Ahn, Sang Hoon; Tak, Won Young; Kweon, Young Oh; Lee, Jung Il; Lee, Kwan Sik; Kim, Hyung Joon; Han, Kwang‐Hyub
• Is Part Of: Journal of gastroenterology and hepatology. Volume 29:Issue 7(2014:Jul.)
• Page Start: 1463
• Page End: 1469
• Publication Date: 2014-07-15
• Subjects: Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.12542
• Languages: English
• ISSNs: 0815-9319

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="jgh12542-sec-0001" sec-type="section"> <title>Background and Aim</title> <p>Sorafenib is recommended as a standard treatment for advanced hepatocellular carcinoma (HCC). The efficacy and safety of sorafenib as a first‐line therapy in Korean patients with advanced HCC were investigated.</p> </sec> <sec id="jgh12542-sec-0002" sec-type="section"> <title>Methods</title> <p>From 2007 to 2012, 86 patients with advanced HCC (Barcelona Clinic Liver Cancer stage C) treated with sorafenib as a first‐line therapy were enrolled from five tertiary hospitals. Predictors of overall survival (OS) and progression‐free survival (PFS) were analyzed.</p> </sec> <sec id="jgh12542-sec-0003" sec-type="section"> <title>Results</title> <p>The median age was 59.5 years, and 71 (82.6%) were males; 57 (66.3%) patients were in Child–Pugh class A. The median OS and PFS were 5.0 (range 4.0–5.9) and 3.2 (range 2.6–3.7) months, respectively. Regarding OS, Child–Pugh class A (6.0 <italic>vs</italic> 2.8 months), tumor diameter < 5 cm (6.0 <italic>vs</italic> 4.3 months), baseline α‐fetoprotein < 200 ng/mL (5.8 <italic>vs</italic> 4.1 months), and the advent of hand‐foot‐skin reaction of ≥ grade 2 (5.9 <italic>vs</italic> 4.0 months) were independent favorable predictors (all <italic>P</italic> < 0.05). Similarly, regarding PFS, Child–Pugh class A (4.3 <italic>vs</italic> 2.1 months), tumor diameter < 5 cm (3.9 <italic>vs</italic> 2.8 months), baseline α‐fetoprotein < 200 ng/mL (5.6 <italic>vs</italic> 2.8 months), and the advent of hand‐foot‐skin reaction of ≥ grade 2 (4.5 <italic>vs</italic> 2.6 months) were independent favorable predictors (all <italic>P</italic> < 0.05). All toxicities during sorafenib treatment were manageable.</p> </sec> <sec id="jgh12542-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Because the efficacy of sorafenib seems marginal in Korean patients with treatment‐naïve HCC, how to select candidates with favorable outcomes should be further investigated.</p> </sec> </abstract>